No significant differences in reactogenicity were noted between dose cohorts, between the first, second and third vaccination, nor between Alhydrogel and saline vaccine groups.
Analyses were performed 20 hours after the administration of the vaccine at the end of the third vaccination cycle (15-week-old mice).
Antibodies became detectable after the second or the third vaccination and reached plateau levels thereafter in mice vaccinated with TNF/CHP nanoparticles (data not shown).
Still, the proportion who received their vaccines later than recommended for the second and third vaccination visits was substantial.
Third, vaccination status could have been misclassified due to receipt of influenza vaccines outside of physician offices (estimated to be about 25% of those vaccinated among elderly adults).
Another cohort of 16 volunteers, including the 2 allergic individuals, were ITH-ST negative when first tested late after their second or third vaccination at 6 7 months.
The fourth volunteer did not receive a third vaccination due to receipt of steroids prior to third vaccination (Group C).
A third vaccination was administered to eleven volunteers at week 36.
Greater antibody responses were seen after the third vaccination than after the first two vaccinations.
Why did Malians who responded to the first two vaccinations, respond poorly to the third vaccination?
One volunteer (N514, in group 1) reported severe pain following the third vaccination with PEV3A.
